Creative BioTherapeutics’ (CBT) story is not just one of scientific discovery and entrepreneurship—it is the story of a couple whose partnership has endured for over four decades, bound by a shared passion to change lives. Like many great stories, it began with two young dreamers finding their way in the world. In the quiet hallways of a Midwestern high school in the 1970s, two teenagers—Anita, with her sharp wit and boundless empathy, and Don, a restless visionary with a microscope permanently lodged in his imagination—found each other. They were an unlikely pair: she, the future physical therapist who saw the human body as a symphony of stories; he, the boy who had written a sixth-grade essay vowing to “cure cancer” after watching his grandmother fade away. But love, like science, thrives on unexpected reactions. For over 40 years, their marriage became a laboratory of shared purpose. Don pursued biochemistry at Notre Dame before joining Abbott Labs to design cutting-edge cancer therapies. Yet corporate constraints stifled him—a breakthrough drug for brain tumors, dismissed because its mechanism was not fully understood, was shelved indefinitely. “Science demands answers,” his bosses said. Don seethed. Somewhere, a clock was ticking. Meanwhile, Anita built her own empire of care. What started in hospitals and chronic pain programs as her growing passion to expand into the ”business of healthcare” to drive more diverse treatments concurrently with a full patient schedule led to finally taking Don’s advice. She started a private practice in the room over the garage—dubbed “Creative Rehab” by their children. Future business ventures were added, but the ghosts of her patients with cancer haunted her: the 16-year-old athlete whose laughter turned to silence after an amputation, the college roommate Carolyn, whose metastatic breast cancer outran every treatment. Their dinner table became a battleground of frustration. Don scribbled equations on napkins; Anita recounted the labyrinth of insurance bureaucracy and systemic failures. “We’re both stuck—you in pharma’s red tape, me still watching my patients die,” she declared one night in 2016. “Let’s burn the playbook.” Don hesitated—the risk was enormous—but Anita’s conviction was gravitational. The next day, he resigned from AbbVie.
Life Science Marketing
Life science marketing is complex. Groundbreaking innovations have the power to change lives, but strict regulations shape how those breakthroughs can be communicated. Every message must strike a delicate balance—accurate, compliant, and compelling—all at once. This is where Pyxis Communications shines. They take the time to truly understand what makes a product or service unique—how it works, why it matters, and the real impact it has on researchers and patients. With this insight, Pyxis pinpoints customers’ key challenges and develops strategic, high-quality content that turns complex ideas into clear, compelling messaging. The agency’s services span messaging and positioning, content development, and graphic design, encompassing everything from articles, white papers, and brochures to ad campaigns, email nurture programs, social media, tradeshows and blogs. “We translate complex science into engaging narratives. The result is a strong, trusted voice in a highly regulated and impactful field,” says Shannon Meirzon, co-founder of Pyxis Communications. Great Content Is In Our DNA Pyxis Communications is built on a passion for storytelling. They believe that even the most technical scientific advancements can be communicated in a way that sparks curiosity and builds real connections. It’s not just about presenting data—it’s about making it meaningful, engaging the right audience, and delivering messages that stick. “At Pyxis, great content is in our DNA. Every campaign is a testament to our commitment to making science both exciting and relatable,” says Heather Beaudoin, co-founder of Pyxis Communications. But great content isn’t just about words—it’s about presentation. A message can be powerful, but if it’s not visually engaging, it risks being overlooked. “That’s why we bring eye-catching design into the equation, using strong graphics and storytelling to turn scientific data into exciting, digestible content,” adds Meirzon. From attention-grabbing advertisements to immersive tradeshow booth designs, Pyxis develops campaigns that connect with audiences on an intellectual and emotional level. .
Cell and Gene Therapy
Cell therapy is no longer a distant promise or shrouded in uncertainty—it has emerged as a new frontier in the fight against numerous health conditions. While the field has advanced rapidly, scalability is the crucial missing piece to unlock its full potential. PBS Biotech steps into this challenge with an innovative approach to cell therapy manufacturing. The company brings personalized, life-changing treatments to patients without compromising quality. It serves the global allogeneic cell therapy market by assisting therapeutic drug developers to make treatments more accessible to a broader patient population. However, the mission goes beyond supporting these immediate developers. “While our primary target is drug manufacturers, the end goal is always about improving patient outcomes. We manufacture single-use bioreactors in larger volumes and faster timelines, enabling researchers to develop cell therapy products that combat chronic conditions like cancer, diabetes and heart failure,” says Brian Lee, CEO. PBS Biotech offers customized, scalable solutions and services by leveraging its innovative Vertical-Wheel technology and deep industry expertise. From expansion to differentiation phases of cell therapy development, the company plays a vital role in advancing this transformative field. .
Drug Discovery and Development
The Rub: Medical Affairs is Far More Than a Commodity in Rare and Genetic Disease
Henry David Cremisi, MD, FACP, Executive Medical Director, Medical Affairs, Caidya
Cell and Gene Therapy
A Call To Action For Rare Diseases
Jeff Sherman, Chief Medical Officer, Horizon
Antibodies
Driving Innovation From Discovery To Clinical Impact At Bristol Myers Squibb
Erick Morris, Senior Director, Translational Research, Oncology, Bristol Myers Squibb
IN MY OPINION
Therapeutic and Medical Device
Challenges and opportunities in gene therapy clinical development
Haichen Yang, MD, MA, MBA, Vice President, Clinical Research, Amicus Therapeutics Inc.
LAST WORD
Life SR Magazine Special
Revolutionize Your Bathroom Cleaning with Microbes
John Harp, Staff Scientist and Product Management, and Yaashviny Nair, Associate Business Development Manager, Novozymes
IN FOCUS
Understanding and Tackling Cancer Drug Resistance
Cancer treatment is one of the most complex treatments among others, and it often encounters several issues. One such issue is the cancer drug resistance.
Redefining Biomanufacturing with Single-Use Bioreactors
The biopharmaceutical industry is experiencing significant transformation, driven by innovations that enhance production processes and improve efficiency. Among the most notable advancements is the widespread adoption of single-use bioreactors
EDITORIAL
Breakthroughs in Drug Resistance and Bioreactors
The integration of artificial intelligence (AI) in drug discovery is transforming life sciences by accelerating drug candidate identification. AI-driven platforms analyze vast datasets to predict molecule interactions, reducing research timelines and costs. Alongside AI, CRISPR gene-editing technology enables precise DNA modifications, allowing scientists to correct genetic mutations and improve cancer therapies. In line with various industry developments, we are featuring Creative BioTherapeutics, the Cancer Drug Resistance Company of the Year, in this edition.
Beyond genetic innovations, manufacturing is evolving with single-use bioreactors, replacing traditional systems to lower contamination risks, cut costs and improve production flexibility, which aligns with the work of single-use bioreactors company of the year showcased in this edition.
In clinical research, digital twin technology streamlines drug development with virtual patient models, enhancing trial efficiency. Meanwhile, the Boutique Marketing Communications Agency highlighted in this edition is driving industry awareness, which helps companies communicate innovations effectively.
The edition also features thought leadership from industry experts, including Erick Morris, senior director, of translational research, oncology at Bristol Myers Squibb, who explores how translational research accelerates drug development by leveraging biomarkers, optimizing clinical transitions and aligning regulatory strategies. Another thought leader, Haichen Yang, vice president, clinical research at Amicus Therapeutics, discusses overcoming gene therapy bottlenecks by addressing regulatory, safety and manufacturing challenges to drive therapeutic advancements.
We are showcasing the top companies in the life sciences space, highlighting their impact on cancer drug resistance, marketing communications and single-use bioreactors.
We hope this edition of Life Science Review helps you explore innovations shaping the future of pharmaceutical advancements.
